Core Insights - Bio-Techne Corporation and Nucleai presented pivotal data from the SECOMBIT clinical trial at the SITC 2025 Annual Meeting, highlighting the importance of spatial biology in immuno-oncology research [1][2] Study Overview - The SECOMBIT trial combined an immuno-oncology multiplex immunofluorescence panel with AI-driven multimodal biomarker analysis, profiling 42 pre-treatment biopsies from metastatic melanoma patients [2][5] - The study utilized Bio-Techne's COMET platform and Nucleai's multimodal spatial operating system to correlate immune cell interactions with clinical outcomes such as progression-free survival (PFS) and overall survival (OS) [2][5] Key Findings - The location and interaction of immune cells within tumors significantly influence treatment success, enabling better predictions of patient responses to therapies [4] - Specific immune activation markers were linked to improved outcomes across different treatment arms, indicating the potential of spatial biomarkers in clinical decision-making [6][4] Clinical Trial Data - The trial data demonstrated that Bio-Techne's and Nucleai's technologies can identify predictive biomarkers in melanoma patients treated with immunotherapy and targeted therapy [5] - The study was recognized as one of the top 150 abstracts from over 1,200 submissions at the SITC 2025 [5] Availability at SITC 2025 - Bio-Techne's spatial biology portfolio, including the new ProximityScope assay, will be showcased at Booth 603, with visual data from the SECOMBIT study presented in Poster 528 [7] Company Background - Bio-Techne Corporation is a global life sciences company with over $1.2 billion in net sales for fiscal 2025, providing tools and reagents for research and clinical diagnostics [8] - Nucleai specializes in AI-powered multimodal spatial biology, integrating high-plex spatial proteomics and clinical data to develop precision medicine products [9]

Core Insights - Bio-Techne Corporation has launched the ProximityScope assay, a spatial solution that integrates with the BOND RX staining platform from Leica Biosystems, enabling visualization of functional protein-protein interactions on fixed tissue with subcellular resolution [1][2][4] Product Features - The ProximityScope assay provides a visual signal only when two proteins are in close proximity, offering insights into biological mechanisms that were previously inaccessible [2] - It works in conjunction with the BOND RX staining system and ACD's RNAscope Multiomic LS kit, allowing for enhanced detection of RNA and protein on the same tissue section [2] - The assay combines high sensitivity, specificity, and low background, addressing limitations of traditional methods like bulk pull-down assays [3] Applications - Key applications include visualizing cell-cell interactions for immune checkpoint studies, analyzing cell surface interactions that activate signaling pathways, evaluating antibody-based therapeutics, and investigating intracellular interactions related to transcriptional activation [4] Industry Context - The ProximityScope assay represents a significant advancement in spatial biology, providing researchers with a powerful automated solution to decode complex biological systems and accelerate therapeutic innovation [3][4] - Bio-Techne generated over $1.2 billion in net sales in fiscal 2025, indicating strong market presence and demand for innovative life science tools [6]